[go: up one dir, main page]

CN102300587B - 用于伤口愈合的氧化剂和光活化剂的组合物 - Google Patents

用于伤口愈合的氧化剂和光活化剂的组合物 Download PDF

Info

Publication number
CN102300587B
CN102300587B CN200980154337.5A CN200980154337A CN102300587B CN 102300587 B CN102300587 B CN 102300587B CN 200980154337 A CN200980154337 A CN 200980154337A CN 102300587 B CN102300587 B CN 102300587B
Authority
CN
China
Prior art keywords
composition
photoactivator
dyes
red
dye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980154337.5A
Other languages
English (en)
Other versions
CN102300587A (zh
Inventor
R·皮尔加利尼
N·劳皮斯
F·贝利尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kehuan Skin Management Technology Guangdong Co ltd
Original Assignee
Klox Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klox Technologies Inc filed Critical Klox Technologies Inc
Priority to CN201510083789.6A priority Critical patent/CN104707143B/zh
Publication of CN102300587A publication Critical patent/CN102300587A/zh
Application granted granted Critical
Publication of CN102300587B publication Critical patent/CN102300587B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14—Preparations for removing make-up
    • A61Q1/145—Tattoo removal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Biotechnology (AREA)

Abstract

本文提供了一种伤口愈合组合物，其包含至少一种氧化剂、至少一种能够活化所述氧化剂的光活化剂，及至少一种选自透明质酸、葡糖胺和尿囊素的愈合因子，以及药学上可接受的载体。此外，本文公开了局部治疗伤口的方法，其使用至少一种氧化剂和至少一种能够活化所述氧化剂的光活化剂，接着照射所述光敏剂。

Description

用于伤口愈合的氧化剂和光活化剂的组合物
背景
(a)领域
公开的主题主要涉及一种伤口愈合组合物及其治疗方法。
(b)相关现有技术
伤口修复过程对手术程序或跌打损伤后恢复组织完整性和功能是基本的。延迟的伤口愈合和手术伤口开裂代表着重大的临床问题。
如Albrecht等在WO 05/032459和WO 05/021094中所描述，使用光敏染料例如赤藓红B、番红O的光动力学疗法已被用于杀灭细菌。光敏染料被用于直接杀灭细菌。这些专利申请中描述的组合物缺乏氧化剂和愈合因子，并且不将它们直接用于促进伤口愈合。
Neuberger等的美国专利第6,056,548号描述了一种使用光敏染料在口腔中杀灭细菌，并促进口腔卫生的方法。这个专利也描述了使用漂白剂过氧化氢，以光漂白和破坏用于杀灭细菌的光敏染料。但是，所使用的组合物未提及愈合因子且不将它们用于直接促进伤口愈合。
Grafe等的WO 08/013962描述了以下组合物的应用，所述组合物包含胶原和可光活化的分子替莫泊芬(mTHPC)，其用于体内交联胶原以增强和稳定胶原支架的微观结构。这个专利还描述该组合物显示出抗微生物的效果，并消毒治疗部位及抑制微生物生长。但是，这些组合物不包含氧化剂或愈合因子，因而通过强化所形成的胶原支架和细菌杀灭促进伤口愈合。
尽管杀灭存在于受伤部位的细菌对伤口愈合是有利的，但是它不直接促进伤口修复。因此，在病理损害、外伤或创伤形成后，非常有需要提供一种用于愈合皮肤损伤和伤口的新组合物以不仅杀灭细菌，而且还改善和加速愈合过程。
发明概述
根据一个实施方案，公开了一种伤口愈合组合物，其包含至少一种氧化剂、至少一种能够活化所述氧化剂的光活化剂(photoactivator)及至少一种选自透明质酸、葡糖胺和尿囊素的愈合因子，以及药学上可接受的载体。
所述氧化剂可选自过氧化氢、过氧化氢脲和过氧化苯甲酰。
所述伤口愈合组合物还可包含至少一种亲水性胶凝剂。
所述亲水性胶凝剂可选自葡萄糖、改性淀粉、甲基纤维素、羧甲基纤维素、丙基纤维素、羟丙基纤维素、carbopol聚合物、藻酸、藻酸钠、藻酸钾、藻酸铵、藻酸钙、琼脂、角叉菜胶、刺槐豆胶、果胶、明胶。
所述光活化剂可选自呫吨衍生物染料、偶氮染料、生物染色剂和类胡萝卜素。
所述呫吨衍生物染料可选自芴染料、荧光酮染料和rhodole染料。
所述芴染料可选自焦宁染料和罗丹明染料。
所述焦宁染料可选自焦宁Y和焦宁B。
所述罗丹明染料可选自罗丹明B、罗丹明G和罗丹明WT。
所述荧光酮染料可选自荧光素和荧光素衍生物。
所述荧光素衍生物可选自焰红染料B、玫瑰红和汞溴红。
所述荧光素衍生物可选自伊红和赤藓红。
所述偶氮染料可选自甲基紫、中性红、对位红、苋菜红、淡红、诱惑红AC(allura red AC)、酒石黄、橘黄G、丽春红4R、甲基红和紫脲酸铵-红紫酸铵。
所述生物染色剂可选自番红O、碱性品红、酸性品红、碘化3，3′-二己基羰花青(3，3′dihexylocarbocyanine iodide)、胭脂红酸和吲哚菁绿。
所述类胡萝卜素可选自藏红花酸、α-藏红花原色素(8，8-双脱辅基-8，8-类胡萝卜素酸(8，8-diapo-8，8-carotenoic acid))、玉米黄素、番茄红素、α-胡萝卜素、β-胡萝卜素、红木素和岩藻黄质。
所述类胡萝卜素可作为选自藏红花红粉、胭脂树橙提取物和褐藻提取物的混合物存在于组合物中。
所述伤口愈合组合物还可包含至少一种螯合剂。
所述螯合剂可选自乙二胺四乙酸(EDTA)和乙二醇四乙酸(EGTA)。
所述伤口愈合组合物还可包含至少一种脂解刺激因子。
所述脂解刺激因子可选自咖啡因和1，7-二甲基黄嘌呤。
根据一个实施方案，公开了一种伤口愈合的方法，其包括以下步骤：a)在患者皮肤上局部施用组合物，所述组合物包含至少一种氧化剂、至少一种能够活化所述氧化剂的光活化剂；及b)将步骤a)所述的皮肤用光化光处理足以使所述光活化剂引起所述氧化剂活化的时间。
所述伤口愈合的方法可包括将皮肤暴露于光化光中达约60秒至约5分钟的时间。
所述伤口愈合的方法可包括将皮肤暴露于光化光中达每cm2待处理区域约60秒至约5分针的时间。
所述伤口愈合的方法可包括将皮肤暴露于在正被处理的区域上连续移动的光化光源中。
所述伤口愈合的方法可包括将皮肤暴露于光化光中，所述光化光可为具有400nm至600nm之间波长的可见光。
以下术语在下面定义。
术语“亲水性胶凝剂”意指稠化和稳定液体溶液、乳剂和悬浮液的物质。当其大部分由液体组成时，亲水性胶凝剂溶于液体中并提供将固体物质外观赋予所得凝胶的结构。亲水性胶凝剂与增稠剂非常相似。
术语“光化光”意指由特定光源(灯、LED或激光)发射并且在与物质(例如以下定义的光活化剂)相互作用时能被该物质吸收并产生可辨别或可测量变化的光能；对于临床可辨别变化，我们可假定使用的光活化剂颜色的变化(例如从红色至透明)。
术语“光活化剂”意指能吸收光化光的化合物。所述光活化剂容易经历光致激发并接着将其能量传递给其它分子，从而增强或加速光的色散，并增强或活化存在于反应混合物中的氧化剂。
术语“氧化剂”意指容易传递氧原子并氧化其它化合物的化合物，或在氧化还原化学反应中获得电子的物质。
术语“螯合剂”意指去除金属离子(例如铁)并将其保存于溶液中的化学制品。
术语“愈合因子”意指促进或增强组织愈合或再生过程的化合物。
术语“脂解”意指脂质被降解成其组成性脂肪酸的过程。
术语“暴露于光化光的时间”意指每次施用光化光时组织、皮肤或伤口暴露于光化光的时间。
术语“暴露于光化光的总时间”意指数次施用光化光后组织、皮肤或伤口暴露于光化光的累积时间。
术语“药学上可接受的载体”意指防腐剂溶液、盐溶液、等渗(约0.9％)盐溶液或约5％的白蛋白溶液、悬浮液、无菌水、磷酸缓冲盐水等。适合递送给患者的其它缓冲剂、分散剂和惰性无毒物质可包含于本发明的组合物中。所述组合物可为溶液剂、悬浮剂或适于给药的任意合适制剂，并通常无菌及不含不需要的颗粒物质。所述组合物可通过常规灭菌技术进行灭菌。
如附图中所描述，本文主题的特点和优点根据以下所选实施方案的详细描述将会变得更显而易见。如会认识到，所公开和要求保护的主题能够在多方面进行改变，所有均不会背离权利要求的范围。因此，认为附图和说明书在本质上是说明性的，而不是限制性的，并且主题的全部范围在权利要求中阐述。
附图简述
图1显示伊红Y不影响细胞的生存力。将Hep G2细胞用渐增浓度(0.001-100μM)的伊红Y处理24小时，或不处理(CTL)。星形孢菌素(STS)被用作引起细胞死亡的阳性对照。较高浓度(0.5和1mM)的伊红Y不可被测试，因为该染料干扰测定。
图2显示赤藓红B不影响细胞的生存力。将Hep G2细胞用渐增浓度(0.001-100μM)的赤藓红B处理24小时，或不处理(CTL)。星形孢菌素(STS)被用作引起细胞死亡的阳性对照。较高浓度(0.5和1mM)的赤藓红B不可被测试，因为该染料干扰测定。
图3显示最初的伤口闭合在施用伤口愈合组合物后得到改善。将带有切除伤口的大鼠(n＝2/组)用或不用伤口愈合组合物处理，所述组合物包含氧化剂(过氧化氢脲)和光活化剂混合物(伊红Y、赤藓红B和藏红花红粉)。棱形：处理的动物；圆圈：未经处理的动物(对照)。
图4显示伤口闭合在施用伤口愈合组合物后得到改善。将带有切除伤口的大鼠(n＝2/组)用或不用伤口愈合组合物(A)、伤口愈合组合物(B)或伤口愈合组合物(C)处理，所述组合物(A)包含氧化剂(过氧化氢脲)和光活化剂混合物(伊红Y、赤藓红B)，所述组合物(B)包含氧化剂(过氧化氢脲)和光活化剂混合物(伊红Y、赤藓红B和藏红花红粉)，所述愈合组合物(C)包含氧化剂(过氧化氢脲)和光活化剂混合物(伊红Y、赤藓红B、藏红花红粉和吲哚菁绿)。
图5显示伤口闭合在施用伤口愈合组合物后得到改善。将带有切除伤口的大鼠(n＝2/组)用或不用伤口愈合组合物处理，所述伤口愈合组合物包含氧化剂(过氧化氢脲)和光活化剂混合物(伊红Y、赤藓红B)。棱形：处理的动物；三角形：未经处理的动物(对照)。
图6显示伤口闭合在施用伤口愈合组合物后得到改善。
图7显示伤口闭合在施用伤口愈合组合物后得到改善。
优选实施方案的详细描述
根据一个实施方案，提供了一种伤口愈合组合物和在患者皮肤或伤口上使用所述组合物的方法。此产品加速伤口愈合和修复。
根据另一个实施方案，提供了一种使用组合物的方法，即光动力技术，其中通过光将该组合物活化，提供对皮肤或伤口有益的效果并促进愈合。
所述组合物和方法可用于治疗不同皮肤层的创伤，创伤包括切口、撕裂、擦伤、刺伤、穿透伤、枪伤、挫伤、血肿和挤压伤。黏膜损伤也可能用本发明组合物治疗，例如可用于治疗口腔黏膜的病理损害，例如牙周炎、溃疡，和唇疱疹(口面部疱疹)。
所述组合物包含多种选自可能组分组的活性成分。这些多种活性成分每种都具有其作用机制。
氧化剂
所述组合物包含氧化剂作为氧自由基的来源。过氧化物化合物为包含过氧基团(R-O-O-R)的氧化剂，过氧基团为包含两个氧原子的链状结构，每个氧原子与另一个氧原子和基团或某种元素键合。用于制备激活媒质的合适氧化剂包括但不限于：
过氧化氢(H2O2)为制备有机过氧化物的起始材料。H2O2是强氧化剂，而过氧化氢独特的性质在于其降解成水和氧气且不形成任何持久的有毒残留化合物。此组合物中使用的过氧化氢可用在凝胶中，例如用6％的过氧化氢。本发明组合物中可使用的过氧化氢的合适浓度范围为约3.5％至约6％。
脲过氧化氢(也被称为过氧化脲、过氧化氢脲或过碳酰胺)可溶于水并含大约35％过氧化氢。所述组合物中使用的过氧化氢脲可用作凝胶剂，例如用表示5.6％过氧化氢的16％过氧化氢脲。本发明组合物中可使用的过氧化脲的合适浓度范围为约10％至约16％。过氧化脲以可用热或光化学反应加速的缓释方式降解成脲和过氧化氢。释放的脲[尿素，(NH2)CO2)]，高度可溶于水且为强蛋白变性剂。它增加一些蛋白质的溶解度并增强皮肤和/或黏膜的再水合。
过氧化苯甲酰由通过过氧化物基团连接的两个苯甲酰基(羧酸的H被移除的苯甲酸)组成。在痤疮的治疗中发现，浓度在2.5％至10％变化时，释放的过氧化物基团有效杀菌。过氧化苯甲酰也促进皮肤更新并清洁毛孔，这进一步有助于减少细菌数并减少痤疮。过氧化苯甲酰与皮肤接触时降解成苯甲酸和氧气，没有一种是有毒的。本发明组合物中可使用的过氧化苯甲酰的合适浓度范围为约2.5％至约5％。
因为其增加的毒性及其与光动力能量传递不可预见的反应，所以应避免包含其它形式的过氧化物(例如有机或无机过氧化物)。
光活化剂：
光活化剂将光能传递给氧化剂。合适的光活化剂可为荧光染料(或染色剂)，但也可采用其它染料类别或染料(生物学和组织学染料、食品着色剂、类胡萝卜素)。混合光活化剂可通过混合的染料分子增加光吸收并增强吸收和光-生物调节选择性。这创造了产生新的光敏性和/或选择性的光活化剂混合物的多种可能性。
光活化剂的有利特性是增加的荧光性。在本发明中，光在绿至黄光谱的二次放射会是有利的，因为这是深穿透波长范围，具有血液的深吸收。这导致血流强烈的增加、血管舒张和血管舒缩现象。合适的光活化剂包括但不限于：
呫吨衍生物：
呫吨衍生物染料已在全世界长时间使用并测试。它们显示出低毒性和增强的荧光性。呫吨类别由3个亚类组成：a)芴；b)荧光酮；和c)rhodole。
芴类别包括焦宁(例如焦宁Y和B)和罗丹明(例如罗丹明B、G和WT)。取决于使用的浓度，焦宁和罗丹明两者可能有毒且其与光的相互作用可能导致毒性增加。rhodole染料类别发生的类似作用是已知的。
荧光酮类别包括荧光素染料和荧光素衍生物。
荧光素是在显微术中常用的荧光团，具有494nm的最大吸收和521nm的最大放射。荧光素的二钠盐被称为D&C Yellow 8。它具有非常高的荧光性但快速光降解。在本发明组合物中，荧光素与其它光活化剂如吲哚菁绿和/或藏红花红粉的混合物将增加这些其它化合物的光吸收。
伊红类别包括伊红Y(四溴荧光素、酸性红87、D&C Red 22)，具有514-518nm的最大吸收，将细胞的细胞质、胶原、肌纤维和红细胞染成强烈的红色；和伊红B(酸性红91、eosin scarlet、二溴-二硝基荧光素)，具有与伊红Y相同的染色特性。因其对使用的光谱：广谱蓝光、蓝至绿光和绿光的敏感性，可使用伊红Y、伊红B或两者的混合物。其组织和生物膜染色性质及其低毒性也是有利的。伊红Y和伊红B均对红细胞染色，因而赋予本发明组合物止血(控制血流或阻挡血流)性质和在施用组合物过程中增加对损伤或伤口软组织的光选择性靶向。
焰红染料B(2，4，5，7-四溴-4，5，6，7-四氯荧光素、D&C Red 28、酸性红92)是荧光素的红色染料衍生物，其通过光氧化作用用于废水的消毒和解毒。它具有535-548nm的最大吸收。它也用作制备光敏染料和药品的中间体。
赤藓红B(酸性红51、四碘荧光素)是樱桃粉红、煤基氟食物染料，用作生物染色剂及生物膜和牙菌斑显示剂，在水溶液中具有524-530nm的最大吸收。它受光降解。由于其对使用光谱的光敏感性及其染色生物膜的能力，赤藓红也用在一些实施方案中。当在感染或污染组织的深口袋(例如在牙周治疗的牙周袋)中使用组合物时，包含赤藓红应为有利的。
玫瑰红(4，5，6，7-四氯-2，4，5，7-四碘荧光素、酸性红94)是具有544-549nm最大吸收的明亮淡蓝粉红(bluish-pink)生物学染料，已被用作染料、生物染色剂和诊断辅助剂。也用在合成化学中以从三线态氧中产生单线态氧。
汞溴红(红汞)是具有508nm最大吸收的荧光素的有机汞二钠盐。它用作防腐剂。
偶氮染料：
偶氮(或重氮)染料共有N-N基团，称为偶氮基团。它们主要用在分析化学中或用作食品着色剂，并且它们是非荧光的。合适的偶氮染料包括：甲基紫、中性红、对位红(颜料红1)、苋菜红(偶氮玉红S)、淡红(偶氮玉红、食品红3、酸性红14)、诱惑红AC(FD&C 40)、酒石黄(FD&C Yellow 5)、橘黄G(酸性橙10)、丽春红4R(食品红7)、甲基红(酸性红2)、紫脲酸铵-红紫酸铵。
生物染色剂：
在对生物材料染色方案中常用的染料分子也可用作光活化剂。合适的生物染色剂包括：
番红(番红O、碱性红2)也是偶氮染料并用在组织学和细胞学中。它在革兰氏染色方案中是标准的复染剂。
品红(碱性或酸性)(盐酸蔷薇苯胺)是洋红生物学染料，其可染色细菌并已用作防腐剂。它具有540-555nm的最大吸收。
碘化3，3′-二己基羰花青(DiOC6)是用于细胞内质网、泡囊膜和线粒体染色的荧光染料。它显示出光动力毒性；当暴露于蓝光时，具有绿色荧光。
胭脂红酸(酸性红4、中性红4)是从胭脂虫中天然获得的红色葡糖苷羟基蒽醌(glucosidal hydroxyanthrapurin)。
吲哚菁绿(ICG)用作血容量确定、心输出量或肝功能的诊断辅助剂。ICG与红细胞强烈结合，当用在与荧光素的混合物中时，ICG增加蓝至绿光的吸收。
类胡萝卜素
类胡萝卜素染料也可充当光活化剂。
藏红花红粉是含天然类胡萝卜素的化合物。藏红花是从番红花获得的香料。其特征在于苦味和碘仿或干草样香味；这些特征是由化合物藏红花苦苷和藏花醛引起的。它也包含赋予其特征性黄-红颜色的类胡萝卜素染料藏红花原色素。
藏红花包含多于150种不同的化合物，其中很多是类胡萝卜素：芒果藏红花原色素(mangicrocin)、reaxanthine、番茄红素，和多种α-和β-胡萝卜素，其显示出良好的光吸收和有益的生物活性。藏红花也可充当光子传递剂和愈合因子。藏红花的颜色主要是α-藏红花原色素(8，8-双脱辅基-8，8-类胡萝卜素酸)的效果。干藏红花红粉对波动的pH水平高度敏感并在光和氧化剂存在下快速化学降解。其更耐热。数据显示藏红花具有抗癌、免疫调节和抗氧化性质。对于吸光度，针对藏红花原色素特定的光子波长440nm(蓝光)来确定。其具有深红色并形成具有186℃熔点的晶体。当溶于水时，形成橙色溶液。
藏红花酸是藏红花的另一种化合物，发现其表现出抗血脂作用和促进氧气在不同组织中渗透。更具体地，观察到毛细血管内皮细胞增加的氧合作用。观察到肌肉和大脑皮层氧合作用的增加，引致在具有诱导的出血性休克或肺气肿的实验动物中存活率增加。
胭脂树橙香料(anatto a spice)含有显示相关抗氧化性质的类胡萝卜素红木素作为主要组分(70％-80％)。
β-胡萝卜素也显示出合适的特性。
岩藻黄质是具有光敏化氧化还原反应的显著能力的褐藻组分。
愈合因子：
愈合因子包括在组合物施用部位促进或增强组织愈合或再生过程的化合物。在组合物光活化过程中，皮肤或黏膜在治疗部位增加分子吸收。在延长的时期内观察到治疗部位处血流的增加。随着愈合因子的加入，由于自由基级联的动态相互作用，淋巴引流的增加和渗透压平衡可能的改变可被增强或甚至强化。合适的愈合因子包括但不限于：
透明质酸(乙酰透明质酸、透明质酸盐)：是非硫酸化的糖胺聚糖，广泛分布于整个结缔组织、上皮组织和神经组织中。它是细胞外基质的主要组分之一，并对细胞增殖和迁移作出重大贡献。乙酰透明质酸是皮肤的主要组分，在皮肤中参与组织修复。它大量存在于细胞外基质中，同时有助于组织流体动力学、细胞运动和增殖及参与大量的细胞表面受体相互作用，特别是包括初级受体CD44的相互作用。透明质酸酶类酶降解乙酰透明质酸。人体中有至少七种类型的透明质酸酶样酶，其中几种是肿瘤抑制剂。透明质酸的降解产物，低聚糖和非常低分子量的透明质酸，显示促血管生成(pro-angiogenic)性质。另外，最近的研究显示，乙酰透明质酸片段但非天然高分子量的乙酰透明质酸，在组织损伤中可诱导巨噬细胞和树突细胞的炎症应答。透明质酸很适合针对皮肤的生物学应用。由于其高生物相容性，透明质酸被用于促进组织再生。目前的研究证明，透明质酸出现在愈合早期以物理地为介导免疫应答的白细胞创造空间。它用在伤口愈合应用的生物支架合成中和皱纹治疗中。
葡糖胺：是人体组织中最丰富的单糖之一及糖基化蛋白质和脂质生物合成中的前体。它通常用在骨关节炎的治疗中。葡糖胺常用的形式是其硫酸盐。葡糖胺显示多种作用，包括抗炎活性、刺激蛋白聚糖合成和蛋白水解酶的合成。葡糖胺可用在本发明组合物中的合适的浓度范围为约1％至约3％。
尿囊素：是glyosilic酸的二酰脲。它具有去角质效果，增加细胞外基质的水含量，增强上层死亡(凋亡)皮肤细胞的脱落，并促进皮肤增殖和伤口愈合。
另外，藏红花可同时充当光子传递剂和愈合因子。
螯合剂：
可以包含螯合剂以在闭合感染口袋和难以到达的损害中促进涂层的去除；螯合剂可充当金属离子淬灭剂和缓冲剂。合适的螯合剂包括但不限于：
乙二胺四乙酸(EDTA)：它是一种氨基酸，用于螯合二价或三价金属离子。EDTA通过4个羧酸基团和2个胺基与金属结合。EDTA与Mn(III)、Fe(III)、Cu(III)、Co(III)形成特别强的络合物，防止血小板聚集和血块形成。它用在齿髓治疗中作为仪器使用中的涂层去除剂。它用来缓冲溶液。
乙二醇四乙酸(EGTA)与EDTA相关，但具有对钙离子比对镁离子高得多的亲和力。它可用于制备类似活细胞内部环境的缓冲溶液，并常用于牙医学，更具体地牙髓病学中去除涂层。
脂解刺激因子：
可包含脂解刺激因子，以将组合物用于美容应用例如皱纹治疗中。
咖啡因和咖啡因的代谢衍生物1，7-二甲基黄嘌呤在脂解过程中可增加以释放甘油和脂肪酸到血流中。
亲水性胶凝剂
伤口愈合组合物也可包含一种或多种亲水性胶凝剂。亲水性胶凝剂增强组合物的稠度并有助于促进组合物应用到皮肤或受伤区域。此外，当与过氧化氢(H2O2)使用时，它可有助于缓慢释放H2O2，并提供更直接的反应，因为纯H2O2可直接使用。合适的亲水性胶凝剂包括但不限于葡萄糖、改性淀粉、甲基纤维素、羧甲基纤维素、丙基纤维素、羟丙基纤维素、carbopol聚合物、藻酸、藻酸钠、藻酸钾、藻酸铵、藻酸钙、琼脂、角叉菜胶、刺槐豆胶、果胶和明胶。
组合物的用途
纳入合适的光敏化合物并用适当波长光源活化，引致过氧化物(氧化剂)源的降解过程和通过光动力现象发生的其它反应的加速。纳入的染料被特定波长的光子照射并激发到更高能态。当光活化剂激发的电子返回到较低能态时，它们发射出较低能级的光子，因而引起较长波长的光的发射(Stokes频移)。在合适的环境中，大部分这种能量转移被传递给氧或活性过氧化氢并导致氧自由基的形成，例如单线态氧。
由组合物活化产生的单线态氧和其它活性氧类被认为以策动力方式(hormetic fashion)运作。也就是说，健康有益的效果通过低暴露于一般有毒刺激(例如活性氧)，通过刺激和调节目标组织细胞中的应激反应途径而带来。对外源产生的自由基(活性氧类)的内源性反应在对外源自由基提高的防御能力中被调节，并引起愈合和再生过程的加速。另外，组合物的活化也将产生抗菌效果。细菌对暴露于自由基的极端敏感使本发明组合物成为实际上的杀菌组合物。
可能的作用机制应为强化的氧化还原信号传递现象，导致产生突出的信号传导过程，在所述过程中细胞将一种信号转化为另一种信号；活化的“第二信使”引起以较小刺激开始的“信号级联”，所述较小刺激通过这些信号的生物监控放大引出大的反应。这些复杂的机制可能通过生长因子活化涉及血管生成现象而作用。
这种方法可描述成光动力学疗法的形式。但是，不像其中光活化激活剂(photoactoactivator)掺于组织结构中的其它光动力技术，在本发明方法中，光活化材料与组织处于简单接触且当被光活化时，充当与组织化学地相互作用的“光动力装置”。另外，光化光穿透组织，而由光活化剂发射的光(较长波长的光)也被组织吸收。
可使用任何光化光源。任何类型的卤素灯、LED或等离子弧灯，或激光可能是合适的。合适的光化光源的主要特征将会是其以适于活化组合物中存在的一种或多种光活化剂的一种或多种波长发射光。在一个实施方案中，使用氩激光。在另一个实施方案中，使用磷酸钛氧钾(KTP)激光(例如GreenLightTM激光)。在又一个实施方案中，LED光固化装置是光化光源。在再一个实施方案中，光化光源是具有400和600nm之间波长的可见光源。另外，光化光源应具有合适的能量密度。非准直光源(LED、卤素灯或等离子灯)合适的能量密度在约900mW/cm2至约2000mW/cm2范围内。激光光源合适的能量密度在约0.5mW/cm2至约0.8mW/cm2范围内。
暴露于光化光的持续时间将依赖于治疗区域表面，和进行治疗的损害、外伤或损伤的类型。组合物的光活化可发生在数秒内或甚至毫秒内，但延长的暴露时间有利于充分利用吸收光、反射光和再发射光对本发明组合物的协同作用及其与治疗中的组织的相互作用。在一个实施方案中，已施用伤口愈合组合物的组织、皮肤或伤口暴露于光化光的时间为60秒至5分钟的时间。在另一个实施方案中，已施用伤口愈合组合物的组织、皮肤或伤口暴露于光化光的时间为每cm2治疗区域60秒至5分钟，以致使10cm2暴露的总时间将为10分钟至50分钟之间。在又一个实施方案中，光化光源在治疗区域上连续移动，持续合适的暴露时间。在再一个实施方案中，施行伤口愈合组合物和光化光的多次施用。在一些实施方案中，组织、皮肤或伤口暴露于光化光至少2、3、4、5、或6次。在一些实施方案中，暴露于光化光前进行伤口愈合组合物的新鲜施用。
备选实施方案
实施例I
通过混合以下组分制备示例性的伤口愈合组合物：
将氧化剂(4mL)和愈合因子(1.5mL)混合，接着与光活化剂(1mL)混合。将由此得到的组合物施用于受伤患者皮肤上，并用由LED光固化装置(蓝光)提供的光化光活化。治疗后移除组合物。
实施例II
通过混合以下组分制备第二种示例性伤口愈合组合物：
将氧化剂(4mL)和愈合因子(1.5mL)混合，接着与光活化剂(1mL)混合。将由此得到的组合物施用于受伤患者皮肤，并用由LED光固化装置(蓝光)提供的光化光活化。治疗后移除组合物。
第二种示例性组合物使用荧光素染料作为组合物中存在的其它染料(吲哚菁绿和藏红花红粉)的光活化剂。将少量荧光素添加到吲哚菁绿和藏红花红粉溶液中引起处于活化其它染料化合物波长的光的再发射，并通过增加建立的临床吸收/再发射标准改善治疗。
吲哚菁绿很好地结合血红蛋白并有助于组织的选择性能量吸收，还有助于用产生的自由基级联靶向这些组织。另外，这种光活化剂混合物能使藏红花呈现红色荧光，而这又改善光动力和生物刺激两种现象。
实施例III
光活化剂伊红Y和赤藓红B的毒性通过测定这些化合物对人体细胞的细胞毒性来评价。具有上皮细胞形态的Hep G2人肝细胞癌细胞用浓度渐增(0.001至100μM)的伊红Y或赤藓红B处理24小时，并评价细胞存活。当与未处理细胞相比较时，渐增浓度的伊红Y(图1)或赤藓红B(图2)不影响细胞生存力。星形孢菌素(STS)被用作诱导细胞死亡的阳性对照并引起剂量依赖作用(图1和2)。类似的结果通过用乳酸脱氢酶(LDH)的释放测量细胞死亡获得。因此，既不是伊红Y也不是赤藓红B导致细胞死亡率增加。
实施例IV
大鼠切除伤口模型
用大鼠的随机皮瓣研究伤口愈合过程，以评价缺血预适应和药理性预适应方法对皮瓣存活的益处，对皮瓣应用血流评估技术，展示血管分流术和研究对皮瓣生存力的影响。用随机皮瓣模型研究本发明组合物对皮瓣存活率和有助于愈合过程的相关调节的影响。
宽1cm乘长2cm的切除伤口在背部中线背侧切出，低于肩胛骨下角2cm。用手术刀片切除皮肤，从伤口边缘切除肉膜和0.5cm的肉膜皮下层。伤口接着与8cm乘8cm大小的标记拍照。将1克伤口愈合组合物施用于伤口(0.5g/cm2)并用蓝色LED光照射3分钟。
实施例V
如上述实施例IV中的描述在大鼠(n＝2/组)上进行切除，将切口用或不用1克伤口愈合组合物的单次施用处理，所述伤口愈合组合物包含氧化剂(过氧化氢脲)和含伊红Y、赤藓红B和藏红花红粉的光活化剂混合物。将切口用LED灯(蓝光)照射3分钟。处理后在10天的时间内评价伤口闭合百分比(图3)。用组合物处理的动物在处理后最初3天的时间段里显示较快的伤口闭合。
实施例VI
如上述实施例IV中的描述在大鼠(n＝2/组)上进行切除，将切口用或不用1克伤口愈合组合物的单次施用处理，所述组合物包含：(A)氧化剂(过氧化氢脲)及含伊红Y和赤藓红B的光活化剂混合物；(B)氧化剂(过氧化氢脲)和含伊红Y、赤藓红B和藏红花红粉的光活化剂混合物；或(C)氧化剂(过氧化氢脲)及含伊红Y、赤藓红B、藏红花红粉和吲哚菁绿的光活化剂混合物。将切口用LED灯(蓝光)照射3分钟。每日评价伤口闭合百分比，评价4天(图4)。用组合物(A)和(B)处理的动物在处理后4天的时间段里显示出改善的伤口闭合。在组合物(C)中加入吲哚菁绿抑制对组合物(A)和(B)观察到的伤口愈合作用。
实施例VII
如上述实施例IV中的描述在大鼠(n＝2/组)上进行切除，将切口用或不用1克包含氧化剂(过氧化氢脲)及包含伊红Y和赤藓红B的光活化剂混合物的伤口愈合组合物的单次施用处理。将切口用LED灯(蓝光)照射3分钟。在12天的时间段里评价伤口闭合百分比(图5)。用组合物处理的动物在处理后最初7天的时间段里显示较快的伤口闭合。
实施例VIII
使用3cm乘9cm(3×9)树脂玻璃模板，在背部皮肤上用手术标记追踪皮瓣，将肩胛骨下角和骨盆上骨作为界限。使用无菌技术将带颅底的纯随机形态皮瓣切下，并通过深筋膜(包括浅筋膜、肉膜、皮下组织和皮肤)被架起。为尽量减少伤口收缩和模拟人体条件，将肉膜的0.5cm皮下层从伤口边缘移除。在1小时内，将不渗透屏障(例如硅酮薄膜)置于皮瓣及其供皮区之间以消除伤口床支持的可能性。然后移除该薄膜，将皮瓣返回到原来的位置并用4/0尼龙缝线以间断方式手术闭合皮瓣边缘。紧随皮瓣的闭合，在皮瓣蒂部外涂13.5g凝胶制剂(0.5g/cm2)并进行辐照。对照不接收任何处理。小心将软膏均匀分布于整个皮瓣。在试验当天制备凝胶制剂。对凝胶+光组别，将动物用凝胶制剂处理，将皮瓣用LED灯辐照3分钟。
实施例IX
如上描述在大鼠(n＝2/组)上进行切除，将切口用或不用凝胶制剂处理，并如实施例VIII所述用LED灯(蓝光)照射。
结果显示因荧光素注射和直接可视化的坏死的直接相关性。针对组织学变化评价活检。处理组的数据显示坏死临床上显著减少1.5倍(在对照和处理组中的坏死百分率分别为45.7(±17.36)对比30.42(±20.18)的平均值，SD)。现在参考图7A，在对照和处理组中皮瓣手术后坏死的临床评价显示，对照组相对于处理组被观察到较高的坏死。
来自对照和处理组活检的苏木精和伊红染色(图7B)表明较多的血管募集(vascular recruitment)发生在处理组中(见其中的黑色箭头)。用于评估胶原原纤维沉积的Masson Trichrome染色(图7C)在放大40倍时显示，相对于对照组，新胶原沉积正发生在处理组中。使用光活化剂和波长特定的光的光动力学治疗，旨在通过刺激皮瓣侧枝的血管募集改善新伤口的局部区域状态(包括其中新胶原的形成)，来增加皮瓣的存活率。
本文描述的实施方案和实施例是对要求保护主题的一般性说明并非限制。本领域技术人员会理解的是，在不背离所要求保护的公开主题的精神和范围的情况下，这些实施方案可如何容易地针对各种应用和以各种方式进行修改和/或调整。在本文中权利要求应理解为包括而不限于所有备选实施方案和本文主题的等同物。本文所用的短语、措词和术语是说明性的并非限制性的。在法律允许范围内，本文引用的所有参考文献均通过引用以其整体结合。会认识到，本文公开的不同实施方案的任何方面可在可能的备选实施方案及特征的备选组合范围内进行组合，所有不同的特征组合应理解为形成所要求保护主题的一部分。

Claims (1)

1. 一种伤口愈合组合物，其包含：
至少一种氧化剂；
至少一种能够活化所述氧化剂的光活化剂，其中所述至少一种光活化剂是伊红；及
至少一种选自透明质酸、葡糖胺和尿囊素的愈合因子；
以及药学上可接受的载体。
2. 权利要求1的组合物，其中所述至少一种光活化剂是伊红Y。
3. 权利要求1的组合物，其中所述氧化剂选自过氧化氢、过氧化氢脲和过氧化苯甲酰。
4. 权利要求1的组合物，其还包含至少一种亲水性胶凝剂。
5. 权利要求4的组合物，其中所述亲水性胶凝剂选自葡萄糖、改性淀粉、甲基纤维素、羧甲基纤维素、丙基纤维素、羟丙基纤维素、carbopol?聚合物、藻酸、藻酸钠、藻酸钾、藻酸铵、藻酸钙、琼脂、角叉菜胶、刺槐豆胶、果胶和明胶。
6. 权利要求1的组合物，其中所述组合物包含至少一种另外的光活化剂，所述光活化剂选自呫吨染料、偶氮染料、生物染色剂和类胡萝卜素。
7. 权利要求6的组合物，其中所述呫吨染料选自芴染料、荧光酮染料和rhodole染料。
8. 权利要求7的组合物，其中所述芴染料选自焦宁染料和罗丹明染料。
9. 权利要求8的组合物，其中所述焦宁染料选自焦宁Y和焦宁B。
10. 权利要求8的组合物，其中所述罗丹明染料选自罗丹明B、罗丹明G和罗丹明WT。
11. 权利要求7的组合物，其中所述荧光酮染料是荧光素。
12. 权利要求7的组合物，其中所述荧光酮染料选自焰红染料B、玫瑰红和汞溴红。
13. 权利要求7的组合物，其中所述荧光酮染料是赤藓红。
14. 权利要求6的组合物，其中所述偶氮染料选自甲基紫、中性红、对位红、苋菜红、淡红、诱惑红AC、酒石黄、橘黄G、丽春红4R、甲基红和紫脲酸铵-红紫酸铵。
15. 权利要求6的组合物，其中所述生物染色剂选自番红O、碱性品红、酸性品红、碘化3,3'-二己基羰花青、胭脂红酸和吲哚菁绿。
16. 权利要求6的组合物，其中所述类胡萝卜素选自藏红花酸、α-藏红花原色素(8,8-双脱辅基-8,8-类胡萝卜素酸)、玉米黄素、番茄红素、α-胡萝卜素、β-胡萝卜素、红木素和岩藻黄质。
17. 权利要求6的组合物，其中所述类胡萝卜素作为选自藏红花红粉、胭脂树橙提取物和褐藻提取物的混合物存在于所述组合物中。
18. 权利要求1-17中任一项的组合物，其还包含至少一种选自乙二胺四乙酸(EDTA)和乙二醇四乙酸(EGTA)的螯合剂。
19. 权利要求1-17中任一项的组合物，其还包含至少一种选自咖啡因和1,7-二甲基黄嘌呤的脂解刺激因子。
20. 包含氧化剂、至少一种能够活化所述氧化剂的光活化剂和愈合因子的伤口愈合组合物在制备用于治疗伤口愈合的药物中的用途，其中所述至少一种光活化剂是伊红，所述愈合因子选自透明质酸、葡糖胺和尿囊素。
21. 权利要求20的用途，其中所述组合物适于局部施用于患者的皮肤上。
22. 权利要求20或21的用途，其中暴露所述组合物于光化光足够的时间引起所述光活化剂活化所述氧化剂。
23. 权利要求20或21的用途，其中暴露所述组合物于光化光中达60秒至5分钟的时间引起所述光活化剂活化所述氧化剂。
24. 权利要求23的用途，其中在已经施用了所述药物的每cm2区域使所述组合物暴露于光化光60秒至5分钟的时间引起所述光活化剂活化所述氧化剂。
25. 权利要求22的用途，其中所述光化光源在需要处理区域上连续移动。
26. 权利要求22的用途，其中所述光化光为具有400 nm至600 nm之间波长的可见光。
CN200980154337.5A 2008-11-07 2009-11-06 用于伤口愈合的氧化剂和光活化剂的组合物 Expired - Fee Related CN102300587B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510083789.6A CN104707143B (zh) 2008-11-07 2009-11-06 用于伤口愈合的氧化剂和光活化剂的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11223508P 2008-11-07 2008-11-07
US61/112235 2008-11-07
PCT/CA2009/001608 WO2010051636A1 (en) 2008-11-07 2009-11-06 Combination of an oxidant and a photoactivator for the healing of wounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510083789.6A Division CN104707143B (zh) 2008-11-07 2009-11-06 用于伤口愈合的氧化剂和光活化剂的组合物

Publications (2)

Publication Number Publication Date
CN102300587A CN102300587A (zh) 2011-12-28
CN102300587B true CN102300587B (zh) 2015-04-01

Family

ID=42152429

Family Applications (4)

Application Number Title Priority Date Filing Date
CN200980154337.5A Expired - Fee Related CN102300587B (zh) 2008-11-07 2009-11-06 用于伤口愈合的氧化剂和光活化剂的组合物
CN201610020876.1A Expired - Fee Related CN105640987B (zh) 2008-11-07 2009-11-06 包含透明质酸、葡糖胺或尿囊素的氧化光活化皮肤再生组合物
CN200980154338.XA Active CN102256591B (zh) 2008-11-07 2009-11-06 包含透明质酸、葡糖胺或尿囊素的氧化光活化皮肤再生组合物
CN201510083789.6A Expired - Fee Related CN104707143B (zh) 2008-11-07 2009-11-06 用于伤口愈合的氧化剂和光活化剂的组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201610020876.1A Expired - Fee Related CN105640987B (zh) 2008-11-07 2009-11-06 包含透明质酸、葡糖胺或尿囊素的氧化光活化皮肤再生组合物
CN200980154338.XA Active CN102256591B (zh) 2008-11-07 2009-11-06 包含透明质酸、葡糖胺或尿囊素的氧化光活化皮肤再生组合物
CN201510083789.6A Expired - Fee Related CN104707143B (zh) 2008-11-07 2009-11-06 用于伤口愈合的氧化剂和光活化剂的组合物

Country Status (25)

Country Link
US (14) US8658219B2 (zh)
EP (4) EP3205355A1 (zh)
JP (10) JP5478631B2 (zh)
KR (5) KR101810148B1 (zh)
CN (4) CN102300587B (zh)
AU (2) AU2009311239B2 (zh)
BR (2) BRPI0921269A2 (zh)
CA (4) CA2936527C (zh)
CY (2) CY1118716T1 (zh)
DK (3) DK2352488T3 (zh)
EA (5) EA024725B1 (zh)
ES (3) ES2632717T3 (zh)
HK (1) HK1211478A1 (zh)
HR (3) HRP20171022T1 (zh)
HU (2) HUE032192T2 (zh)
IL (4) IL212559A (zh)
LT (2) LT2352488T (zh)
MX (3) MX376877B (zh)
NZ (5) NZ592651A (zh)
PL (3) PL3150210T3 (zh)
PT (3) PT3150210T (zh)
SG (2) SG10201703078QA (zh)
SI (2) SI2352488T1 (zh)
SM (2) SMT201700155T1 (zh)
WO (2) WO2010051636A1 (zh)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
PL1951184T3 (pl) 2005-11-09 2012-06-29 Valeant Pharmaceuticals Int Inc Kompozycje do wybielania zębów i sposoby
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
CN101896204B (zh) 2007-11-16 2015-05-20 爱力根有限公司 用于治疗紫癜的组合物及方法
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
EP2324064B1 (en) 2008-09-02 2017-11-08 Tautona Group LP Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
EP3205355A1 (en) 2008-11-07 2017-08-16 KLOX Technologies, Inc. Combination of an oxidant and a photoactivator
AU2014203119B2 (en) * 2009-07-17 2016-06-09 Klox Technologies Inc. Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
PL2453922T3 (pl) 2009-07-17 2018-03-30 Klox Technologies Inc. Przeciwbakteryjna doustna kompozycja
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
FR2957254B1 (fr) 2010-03-12 2016-10-14 Allergan Ind Sas Compositions fluides pour ameliorer les etats de la peau
EP3078388B1 (en) 2010-03-22 2019-02-20 Allergan, Inc. Cross-linked hydrogels for soft tissue augmentation
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
KR102154944B1 (ko) 2011-06-03 2020-09-11 알러간 인더스트리 에스에이에스 항산화제를 포함하는 피부 충전제 조성물
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US11116841B2 (en) 2012-04-20 2021-09-14 Klox Technologies Inc. Biophotonic compositions, kits and methods
WO2014015274A1 (en) 2012-07-20 2014-01-23 The General Hospital Corporation Methods for tissue passivation
US10549112B2 (en) 2012-07-20 2020-02-04 The General Hospital Corporation Apparatus for tissue irradiation and methods and kits utilizing the same
KR20210072827A (ko) * 2012-09-14 2021-06-17 광동 클록스 바이오메디컬 그룹 씨오., 엘티디 생체 광자성 용도를 위한 발색단 조합
AU2013315304A1 (en) * 2012-09-14 2015-03-26 Klox Technologies Inc. Cosmetic biophotonic compositions
EP2895139B1 (en) 2012-09-14 2019-10-23 Bausch Health Companies Inc. Methods for teeth whitening
JP6116842B2 (ja) * 2012-09-25 2017-04-19 国立大学法人 東京大学 標的細胞特異的な光増感用化合物。
US20140276354A1 (en) * 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
CN103432581A (zh) * 2013-03-22 2013-12-11 北京海思威科技有限公司 速立氧注射剂在制备治疗疾病的病毒灭活中的应用
JP6281913B2 (ja) 2013-03-29 2018-02-28 国立大学法人三重大学 生体染色剤
CN105431515A (zh) 2013-05-24 2016-03-23 宝洁公司 低ph洗涤剂组合物
RU2016103321A (ru) * 2013-07-03 2017-08-08 Клокс Текнолоджиз Инк. Композиции и способы для лечения незаживающих ран
CA2918539C (en) 2013-07-18 2025-11-18 The General Hospital Corporation ANATOMICAL VESSEL PROCESSING SYSTEMS, METHODS AND ASSOCIATED KITS
EP3065699A1 (en) * 2013-11-05 2016-09-14 Nestec S.A. Use of glucosamine-enriched plant compositions
KR20160140716A (ko) * 2014-04-01 2016-12-07 클록스 테크놀로지스 인크. 조직 필러 조성물 및 사용 방법
US11266685B2 (en) 2014-06-09 2022-03-08 Klox Technologies Inc. Silicone-based biophotonic compositions and uses thereof
AR100864A1 (es) * 2014-06-09 2016-11-09 Klox Tech Inc Composiciones biofotónicas termoendurecibles y sus usos
CN106714843A (zh) * 2014-06-24 2017-05-24 克洛克斯科技公司 包含卤素的生物光子组合物及其用途
CN106659663A (zh) * 2014-06-30 2017-05-10 纽璀克斯技术公司 控制影响角化细胞和/或成纤维细胞和真皮的皮肤失调和皮肤老化的组合产品和美容组合物
WO2016010765A1 (en) * 2014-07-18 2016-01-21 Dabney Paul Medical and veterinary applications of light to therapeutic compounds
US10016456B2 (en) * 2014-07-18 2018-07-10 Dabney Patents, L.L.C. Methods for treating acne vulgaris
WO2016051219A1 (en) 2014-09-30 2016-04-07 Allergan Industrie, Sas Stable hydrogel compositions including additives
AU2015337786B2 (en) 2014-10-31 2020-03-26 Klox Technologies Inc. Photoactivatable fibers and fabric media
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
EP3653232A1 (en) 2015-02-13 2020-05-20 Allergan Industrie, SAS Implants for sculpting, augmenting or correcting facial features such as the chin
CN105031649A (zh) * 2015-08-27 2015-11-11 厦门大学 一种掺杂自组装纳米纤维结构及其制备方法
WO2017075376A2 (en) * 2015-10-30 2017-05-04 Dabney Patents, L.L.C. System, apparatus, and method of providing tattoo fading and removal
CN105342915A (zh) * 2015-11-19 2016-02-24 山东朱氏堂医疗器械有限公司 一种光子冷凝胶及其制备方法
JP7302967B2 (ja) * 2016-01-11 2023-07-04 ベトキノール ソシエテ アノニム 膿皮症治療のためのバイオフォトニック組成物
EP3402524A4 (en) * 2016-01-11 2019-08-07 Klox Technologies Limited BIOPHOTONIC COMPOSITIONS FOR THE TREATMENT OF SKIN AND SOFT PARTICLES WITH NON-RESISTANT AND RESISTANT INFECTIONS
CA3011156A1 (en) 2016-01-11 2017-07-20 Klox Technologies Limited Biophotonic compositions for the treatment of otitis externa
CN107837209A (zh) * 2016-09-21 2018-03-27 张黎 一种纹绣无痕清洗液
EP3515497A4 (en) 2016-09-23 2020-05-13 Klox Technologies Inc. BIOPHOTONIC COMPOSITIONS, METHODS AND KITS FOR INHIBITING AND DISRUPTIONING ORGANIC FILMS
JP2018048100A (ja) * 2016-09-23 2018-03-29 クロクス テクノロジーズ インコーポレイテッド 疼痛の軽減のためのバイオフォトンの組成物、方法およびキット
WO2018145208A1 (en) * 2017-02-08 2018-08-16 Klox Technologies Inc. Biophotonic methods for increasing in situ energy production and energy emission in biological cells and tissues
CN110650753A (zh) * 2017-02-22 2020-01-03 通用医疗公司 用于伤口愈合的光化学处理方法
WO2019095072A1 (en) * 2017-11-17 2019-05-23 Klox Technologies Limited Biophotonic compositions, methods and kits for enhancing hair growth
RU2699362C2 (ru) * 2018-01-16 2019-09-05 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НОВАСКИН" (ООО "Новаскин") Композиция на основе наночастиц диоксида церия и полисахаридов бурых водорослей для лечения ран
KR102012581B1 (ko) * 2018-01-22 2019-08-20 주식회사 디알나노 메틸렌블루 혼합물을 포함하는 패치형 창상피복재
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
KR20210136009A (ko) * 2019-01-31 2021-11-16 펄스테라 코포레이션 살균방법 및 조성물
CN109999225B (zh) * 2019-04-24 2021-06-08 温州医科大学 一种骨修复材料及其制备方法
JP7405543B2 (ja) * 2019-09-19 2023-12-26 オリザ油化株式会社 経口美肌用組成物
KR102309402B1 (ko) * 2019-12-03 2021-10-07 한국에너지기술연구원 광에너지 방출 물질을 포함하는 시트
US12433964B2 (en) 2020-05-07 2025-10-07 Purdue Research Foundation Antiviral and antibacterial disinfection aero-solution using edible food dyes
RU2753794C1 (ru) * 2021-02-04 2021-08-23 Никита Андреевич Чунихин Способ лечения хронических периодонтитов с применением технологии трансканальной лазерной беспигментной фотоабляции
IT202100014150A1 (it) * 2021-05-31 2022-12-01 Vs Ortho Societa’ A Responsabilita’ Limitata Lampada dentale foto-polimerizzante
CN115054539B (zh) * 2021-08-27 2024-06-18 湖南科洛克医药有限公司 一种消炎祛疤凝胶的制备工艺
CN115054567B (zh) * 2021-08-30 2024-10-01 湖南科洛克医药有限公司 一种皮肤创口修护凝胶及其使用方法和应用
IT202200000689A1 (it) * 2022-01-18 2023-07-18 Marco Balato Impiego di coloranti nell’identificazione selettiva di siti infetti nelle infezioni biofilm correlate
JP7587639B2 (ja) * 2022-10-25 2024-11-20 ロート製薬株式会社 アクネ菌バイオフィルム破壊組成物
CN115487340B (zh) * 2022-10-31 2023-11-17 振德医疗用品股份有限公司 一种负载活性氧的细菌纤维素敷料及其制备方法
CN115957331B (zh) * 2022-12-08 2025-07-11 沈阳药科大学 一种除疤痕凝胶剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021834A1 (en) * 1996-08-07 2003-01-30 Petito George D. Method for use of hyaluronic acid in wound management
US20080255498A1 (en) * 2005-08-25 2008-10-16 Houle Philip R Sensitizer Solutions, Systems, and Methods of Use
CN102256591A (zh) * 2008-11-07 2011-11-23 克洛克斯科技公司 包含透明质酸、葡糖胺或尿囊素的氧化光活化皮肤再生组合物

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA495814A (en) * 1953-09-08 H. Gorin Manuel Antiseptic wound dressing
US2877221A (en) * 1954-03-17 1959-03-10 Pfizer & Co C 11, 14-peroxides of substituted ergostadiene compounds
US3309274A (en) 1962-07-23 1967-03-14 Brilliant Herbert Use of fluorescent dyes in dental diagnostic methods
US3293127A (en) 1964-07-22 1966-12-20 Gold Crest Chemical Corp Inc Arterial embalming fluid and method for embalming therewith
DE1617744A1 (de) * 1964-07-24 1970-09-10 Peter Strong & Co Inc Reinigungsmittel fuer Zahnprothesen
NL152290B (nl) 1965-09-08 1977-02-15 American Cyanamid Co Werkwijze ter bereiding van chemiluminescerende mengsels.
US3372125A (en) * 1965-11-15 1968-03-05 Peter Strong & Company Inc Denture cleanser
US3595798A (en) * 1967-12-18 1971-07-27 Lever Brothers Ltd Cleansing compositions
US3671450A (en) 1969-09-22 1972-06-20 American Cyanamid Co Chemiluminescent compositions
US3728446A (en) * 1971-01-11 1973-04-17 Colgate Palmolive Co Speckled dentifrice gel
FR2463613A1 (fr) 1979-08-20 1981-02-27 Thorel Jean Noel Nouvelles compositions pour la revelation de la plaque dentaire
US4574097A (en) 1984-08-10 1986-03-04 Isopedix Corporation Reinforced thixotropic gel composition
US4846165A (en) 1986-11-26 1989-07-11 Dentsply Research & Development Corp. Wound dressing membrane
JPH01279838A (ja) 1988-04-30 1989-11-10 Kiyuukiyuu Yakuhin Kogyo Kk 塩化リゾチーム含有歯肉炎・歯槽膿漏用貼付剤
US4891211A (en) * 1988-06-29 1990-01-02 Church & Dwight Co., Inc. Stable hydrogen peroxide-releasing dentifice
EP0356868A3 (en) 1988-09-01 1991-03-20 Dentsply International, Inc. A method of treating a tooth with adhesive dental cavity basing composition
NL8900165A (nl) 1989-01-24 1990-08-16 Matthijs Cornelis Evers Wondpoeder.
EP0423266A4 (en) 1989-02-28 1991-09-25 Marc N Benhuri Method and composition for treatment of periodontal disease
JPH0383927A (ja) 1989-08-25 1991-04-09 Sunstar Inc 歯周組織再生促進剤
US4992256A (en) 1989-09-27 1991-02-12 Colgate-Palmolive Company Plaque disclosing compositions
DE4007428A1 (de) * 1990-03-09 1991-09-12 Hoechst Ag Photopolymerisierbares gemisch und daraus hergestelltes aufzeichnungsmaterial
US5749968A (en) 1993-03-01 1998-05-12 Focal, Inc. Device for priming for improved adherence of gels to substrates
US5800373A (en) 1995-03-23 1998-09-01 Focal, Inc. Initiator priming for improved adherence of gels to substrates
US5705357A (en) 1994-08-29 1998-01-06 Johnson & Johnson Clinical Diagnostics, Inc. Chemiluminescent reagent and assay using a substituted acetanilide for light generation
US5599342A (en) * 1995-01-27 1997-02-04 Candela Laser Corporation Method for treating pigmentation abnormalities using pulsed laser radiation with an elongated cross-section and apparatus for providing same
ATE369402T1 (de) 1995-03-23 2007-08-15 Genzyme Corp Redox und photoinitiatorsystem zur grundierung von verbesserter adhäsion von gelen zu substraten
US5658148A (en) * 1995-04-26 1997-08-19 Ceramoptec Industries, Inc. Dental laser brushing or cleaning device
US6056548A (en) * 1995-04-26 2000-05-02 Ceramoptec Industries, Inc. Hygienic dental laser photo treatment method
JPH092925A (ja) 1995-06-16 1997-01-07 Shiseido Co Ltd ２剤混合式化粧料
WO1997011676A1 (en) * 1995-09-25 1997-04-03 Robert Eric Montgomery Tooth bleaching compositions
US5713738A (en) 1995-12-12 1998-02-03 Britesmile, Inc. Method for whitening teeth
AU4185397A (en) 1996-09-16 1998-04-02 Procter & Gamble Company, The Antimicrobial oral care compositions
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US7353829B1 (en) 1996-10-30 2008-04-08 Provectus Devicetech, Inc. Methods and apparatus for multi-photon photo-activation of therapeutic agents
US7390668B2 (en) * 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6846182B1 (en) * 1996-11-27 2005-01-25 Jeffrey A. Sibner Dental bleaching composition and method
WO1998023219A1 (en) 1996-11-27 1998-06-04 Sibner Jeffrey A Dental bleaching composition and method
US8182473B2 (en) 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
FR2756741B1 (fr) * 1996-12-05 1999-01-08 Cird Galderma Utilisation d'un chromophore dans une composition destinee a etre appliquee sur la peau avant un traitement laser
JPH10182390A (ja) 1996-12-25 1998-07-07 Lion Corp 口腔用組成物
US6391283B1 (en) 1997-01-10 2002-05-21 Ultradent Products, Inc. Methods and apparatus for activating dental compositions
US5785527A (en) * 1997-01-10 1998-07-28 Ultradent Products, Inc. Stable light or heat activated dental bleaching compositions
US5858332A (en) * 1997-01-10 1999-01-12 Ultradent Products, Inc. Dental bleaching compositions with high concentrations of hydrogen peroxide
TW460450B (en) 1997-01-30 2001-10-21 Ciba Sc Holding Ag Specific non-volatile dimeric phenylglyoxalic ester compounds and photopolymerizable compositions comprising said compounds
US6305936B1 (en) 1997-02-19 2001-10-23 Ultradent Products, Inc. Polymerizable isolation barriers with reduced polymerization strength and methods for forming and using such barriers
US6084005A (en) * 1997-02-24 2000-07-04 Kuraray Co., Ltd. Antimicrobial caries-detecting composition
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
JPH10330235A (ja) 1997-06-02 1998-12-15 Lion Corp 義歯洗浄剤
US6108850A (en) * 1997-06-03 2000-08-29 Mclaughlin; Gerald Accelerated method and instrumentation for whitening teeth
US6161544A (en) * 1998-01-28 2000-12-19 Keratoform, Inc. Methods for accelerated orthokeratology
US20030198605A1 (en) * 1998-02-13 2003-10-23 Montgomery R. Eric Light-activated tooth whitening composition and method of using same
US6162055A (en) * 1998-02-13 2000-12-19 Britesmile, Inc. Light activated tooth whitening composition and method of using same
ATE395876T1 (de) 1998-02-13 2008-06-15 Britesmile Professional Inc Durch licht aktiviertes zahnbleich-mittel und anwendungsverfahren
US6149895A (en) * 1998-02-17 2000-11-21 Kreativ, Inc Dental bleaching compositions, kits & methods
US5977199A (en) 1998-02-17 1999-11-02 The Kerr Corporation Composition, delivery system therefor, and method for making temporary crowns and bridges
AU3371799A (en) 1998-03-30 1999-10-18 Fibermark, Inc. Light-activated antimicrobial polymeric materials
US6036493A (en) * 1998-07-23 2000-03-14 Ad Dent Inc. Dental bleaching system and method
US7648695B2 (en) * 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
JP4199333B2 (ja) 1998-08-07 2008-12-17 宇部マテリアルズ株式会社 歯磨組成物
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6030222A (en) * 1998-12-01 2000-02-29 Tarver; Jeanna G. Dye compositions and methods for whitening teeth using same
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6423697B1 (en) 1999-01-14 2002-07-23 Mark Friedman Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache, facial pain, and cervical-muscle spasm
US6420455B1 (en) * 1999-06-18 2002-07-16 3M Innovative Properties Company Antimicrobial composition containing photosensitizers articles, and methods of use
IT1306679B1 (it) 1999-06-29 2001-10-02 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della
US6365134B1 (en) * 1999-07-07 2002-04-02 Scientific Pharmaceuticals, Inc. Process and composition for high efficacy teeth whitening
NL1012696C2 (nl) 1999-07-23 2001-01-24 Berg Electronics Mfg Stekker of contrastekker voor gebruik in een voedingsconnector.
JP5689573B2 (ja) 1999-08-13 2015-03-25 プロヴェクタス ファーマテック，インク． 疾患の光線力学的療法のための改良された局所用薬品および方法
US7220438B2 (en) * 1999-09-23 2007-05-22 Asac Compañia de Biotecnologia Pharmacological activities of Curcuma longa extracts
US6905672B2 (en) * 1999-12-08 2005-06-14 The Procter & Gamble Company Compositions and methods to inhibit tartar and microbes using denture adhesive compositions with colorants
US6475497B1 (en) * 1999-12-08 2002-11-05 The Procter & Gamble Company Tartar control denture adhesive compositions
ATE281820T1 (de) 1999-12-08 2004-11-15 Procter & Gamble Zahnprothesenhaftmittel zur kontrolle der zahnsteinbildung
US6475498B1 (en) 1999-12-08 2002-11-05 The Procter & Gamble Company Method to inhibit tartar and stain using denture adhesive compositions
US6444725B1 (en) * 2000-01-21 2002-09-03 3M Innovative Properties Company Color-changing dental compositions
JP4271339B2 (ja) * 2000-03-31 2009-06-03 富士フイルム株式会社 サーマルヘッドの製造方法
US6267976B1 (en) 2000-04-14 2001-07-31 Gojo Industries, Inc. Skin cleanser with photosensitive dye
US6800671B1 (en) 2000-04-21 2004-10-05 Britesmile, Inc. Low peak exotherm curable compositions
JP2004509672A (ja) 2000-09-14 2004-04-02 ハイ　テク　レーザー 歯のブリーチングのための方法および組成
US6528555B1 (en) * 2000-10-12 2003-03-04 3M Innovative Properties Company Adhesive for use in the oral environment having color-changing capabilities
DE10056114A1 (de) * 2000-11-04 2002-05-29 Wolfgang Malodobry Narbenfreie Entfernung von Tätowierungen
US6485709B2 (en) 2001-01-23 2002-11-26 Addent Inc. Dental bleaching gel composition, activator system and method for activating a dental bleaching gel
JP2002233612A (ja) 2001-02-07 2002-08-20 Daito Giken:Kk 遊技台
JP2002293747A (ja) * 2001-03-29 2002-10-09 Jinen:Kk 皮膚外用剤
DE60239528D1 (de) 2001-05-01 2011-05-05 Corium International Redwood City Zweiphasige, wasserabsorbierende bioadhäsive zusammenstezung
US6676816B2 (en) 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
ITMI20011315A1 (it) 2001-06-21 2002-12-21 Herbariorum Medicaminum Offici Composizione per pasta dentifricia antiplacca con rilevatore di placca
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
US6558653B2 (en) * 2001-09-19 2003-05-06 Scot N. Andersen Methods for treating periodontal disease
FR2833841B1 (fr) * 2001-12-21 2005-07-22 Galderma Res & Dev Gel comprenant au moins un retinoide et du peroxyde de benzoyle
WO2003061696A2 (en) 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
US7081128B2 (en) 2002-03-04 2006-07-25 Hart Barry M Phototherapy device and method of use
US6960079B2 (en) * 2002-04-18 2005-11-01 3M Innovative Properties Company Orthodontic adhesives and appliances including an adhesive on the base of the appliance
WO2003100261A2 (en) 2002-05-07 2003-12-04 Atair Aerospace, Inc. Pneumatic riser release
US6949240B2 (en) 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US6786274B2 (en) 2002-09-12 2004-09-07 York International Corporation Heat exchanger fin having canted lances
US20050098766A1 (en) 2002-09-19 2005-05-12 Watson David L.Jr. Chemiluminescent processes and systems
GB0222091D0 (en) 2002-09-24 2002-10-30 Boots Co Plc Dental compositions and methods
CA2501949A1 (en) * 2002-10-11 2004-04-22 Novocell, Inc. Implantation of encapsulated biological materials for treating diseases
WO2004052238A2 (en) 2002-12-10 2004-06-24 University Of Florida Phototherapy bandage
CN1506042A (zh) * 2002-12-11 2004-06-23 苏加璐 使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物
AU2003290142A1 (en) 2003-01-02 2004-07-29 Metso Paper, Inc. Multiroll calender
AU2004224426A1 (en) * 2003-02-10 2004-10-07 Palomar Medical Technologies, Inc. Light emitting oral appliance and method of use
US7157502B2 (en) 2003-02-19 2007-01-02 Pulpdent Corporation Polymerizable dental barrier material
WO2004081222A2 (en) 2003-03-14 2004-09-23 Sol-Gel Technologies Ltd. Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
US7114953B1 (en) 2003-04-25 2006-10-03 Wagner Eugene C Tooth whitening appliance having membrane covered applicator
JP2003339875A (ja) * 2003-06-16 2003-12-02 Hirokatsu Kimura 入れ墨消去装置
AU2004253463B2 (en) 2003-06-16 2010-12-09 Loma Linda University Medical Center Deployable multifunctional hemostatic agent
GB0314210D0 (en) * 2003-06-18 2003-07-23 Unilever Plc Laundry treatment compositions
KR100960687B1 (ko) 2003-06-24 2010-06-01 엘지디스플레이 주식회사 구리(또는 구리합금층)를 포함하는 이중금속층을 일괄식각하기위한 식각액
JP4219756B2 (ja) 2003-07-23 2009-02-04 京セラ株式会社 携帯端末装置
EP2263788B1 (en) 2003-07-31 2018-07-25 Sol-Gel Technologies Ltd. A process for the preparation of microcapsules filled with active ingredients
US7148066B2 (en) * 2003-08-01 2006-12-12 Glotell Products, Inc. Dye solutions for use in methods to detect the prior evaporation of anhydrous ammonia and the production of illict drugs
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20050042712A1 (en) 2003-08-22 2005-02-24 Advanced Medical Optics, Inc. Methods, compositions and instruments to predict antimicrobial or preservative activity
US20050049228A1 (en) 2003-09-02 2005-03-03 Ceramoptec Industries Inc. Antimicrobial photodynamic therapy compound and method of use
US20050059731A1 (en) * 2003-09-16 2005-03-17 Ceramoptec Industries, Inc. Erythrosin-based antimicrobial photodynamic therapy compound and its use
US20050175541A1 (en) * 2003-11-19 2005-08-11 Lanza Gregory M. Enhanced drug delivery
US20070244195A1 (en) 2004-05-18 2007-10-18 Burkhart Craig N Treatment methods with peroxides and tertiary amines
JP4496375B2 (ja) * 2004-05-21 2010-07-07 国立大学法人鳥取大学 創傷の治療又は処置のための薬剤
US20050281890A1 (en) * 2004-06-18 2005-12-22 San Chandan K Methods and compositions for wound healing
EP1784154A1 (en) 2004-07-08 2007-05-16 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
GB0420888D0 (en) * 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
CA2486475A1 (en) 2004-11-02 2006-05-02 John Kennedy Method of treating microorganisms in the oral cavity
ATE486636T1 (de) 2004-11-09 2010-11-15 Discus Dental Llc Zweikomponenten-zahnbleichzusammensetzungen
US20080274999A1 (en) * 2005-01-03 2008-11-06 Novozymes Biopolymer A/S Hyaluronic Acid Fraction with Moisturizing and Anti-Wrinkle Properties
WO2006089028A2 (en) * 2005-02-15 2006-08-24 Lab39, Llc Foaming compositions and methods
EP1733762A1 (en) 2005-05-25 2006-12-20 3M Espe AG Dental composition for detection of carious tissue, detection method
EP1906947A4 (en) 2005-06-13 2012-11-14 Univ Singapore LIGHT-SENSITIVE COMPOSITION AND ITS USES
WO2007001926A2 (en) * 2005-06-24 2007-01-04 Hyperbranch Medical Technology, Inc. Low-swelling hydrogel sealants for wound repair
WO2007030666A2 (en) * 2005-09-07 2007-03-15 Herbal Intervention Corporation Medicated skin care preparation for promoting wound healing
US20070092469A1 (en) * 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
EP1779891A1 (en) * 2005-10-28 2007-05-02 Abdula Kurkayev Method of activating a photosensitizer
PL1951184T3 (pl) 2005-11-09 2012-06-29 Valeant Pharmaceuticals Int Inc Kompozycje do wybielania zębów i sposoby
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
CA2635947A1 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Enzyme and photobleach containing compositions
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
EP2068622A4 (en) 2006-07-28 2012-10-10 Ceramoptec Gmbh METHOD AND MIXTURE FOR IN VIVO PHOTOCHEMICAL RETICULATION OF COLLAGEN
JP5559540B2 (ja) 2006-10-24 2014-07-23 カリフォルニア・インスティテュート・オブ・テクノロジー 体組織の機械的および／または化学的性質に影響を及ぼすための光化学療法
US20080108681A1 (en) * 2006-10-27 2008-05-08 Access Business Group International Llc Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
US20080113037A1 (en) * 2006-11-10 2008-05-15 Green Barbara A Topical Compositions Comprising Polyhydroxy Acids and/or Lactones for Improved Cutaneous Effects of Oxidative Therapeutic Drugs
EP2117575A4 (en) 2007-01-03 2013-06-05 Burnham Inst Medical Research METHOD AND COMPOSITIONS RELATED TO GERYL BINDING COMPOUNDS
US8334328B2 (en) 2007-02-09 2012-12-18 Klox Technologies Inc. Photopolymerization material for gums isolation
CN101970560A (zh) 2008-01-08 2011-02-09 奎克-麦德技术公司 醇可溶性的季铵聚合物消毒剂
WO2009089345A2 (en) 2008-01-08 2009-07-16 Blazetrak, Llc Review managment system for audition portfolios
PL2453922T3 (pl) * 2009-07-17 2018-03-30 Klox Technologies Inc. Przeciwbakteryjna doustna kompozycja
JP5932653B2 (ja) 2009-10-27 2016-06-08 クロクス テクノロジーズ インコーポレイテッド 光線療法における個人的使用のためのデバイス
GB201012217D0 (en) 2010-07-21 2010-09-08 Republic Polytechnic Compounds for photodynamic therapy
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US8658466B2 (en) * 2012-06-18 2014-02-25 Chipbond Technology Corporation Semiconductor package structure and method for making the same
KR20210072827A (ko) 2012-09-14 2021-06-17 광동 클록스 바이오메디컬 그룹 씨오., 엘티디 생체 광자성 용도를 위한 발색단 조합
BR112015020804A2 (pt) 2013-03-01 2017-07-18 Klox Tech Inc dispositivo fototerapeutico, método e uso

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021834A1 (en) * 1996-08-07 2003-01-30 Petito George D. Method for use of hyaluronic acid in wound management
US20080255498A1 (en) * 2005-08-25 2008-10-16 Houle Philip R Sensitizer Solutions, Systems, and Methods of Use
CN102256591A (zh) * 2008-11-07 2011-11-23 克洛克斯科技公司 包含透明质酸、葡糖胺或尿囊素的氧化光活化皮肤再生组合物

Also Published As

Publication number Publication date
JP5996077B2 (ja) 2016-09-21
US10384072B2 (en) 2019-08-20
MX339255B (es) 2016-05-18
EP2352488A1 (en) 2011-08-10
EA201792479A3 (ru) 2018-09-28
KR101835047B1 (ko) 2018-03-08
PT3150210T (pt) 2019-09-04
US8974833B2 (en) 2015-03-10
JP5996066B2 (ja) 2016-09-21
CN104707143B (zh) 2018-04-27
CY1119174T1 (el) 2018-02-14
EP3150210B1 (en) 2019-05-22
CA2742942C (en) 2016-09-06
US20150306131A1 (en) 2015-10-29
KR20110090983A (ko) 2011-08-10
JP5478631B2 (ja) 2014-04-23
MX2011004868A (es) 2011-10-17
EA201792479A2 (ru) 2018-04-30
CN104707143A (zh) 2015-06-17
SG10201703078QA (en) 2017-05-30
US20140221902A1 (en) 2014-08-07
JP2016020386A (ja) 2016-02-04
SMT201700335T1 (it) 2017-09-07
EA201300898A1 (ru) 2014-04-30
HK1225610A1 (zh) 2017-09-15
US20170049802A1 (en) 2017-02-23
SI2365829T1 (sl) 2017-10-30
JP2013253110A (ja) 2013-12-19
PL2352488T3 (pl) 2017-07-31
SG10201703071YA (en) 2017-06-29
US10149985B2 (en) 2018-12-11
PL3150210T3 (pl) 2019-12-31
HUE045950T2 (hu) 2020-01-28
NZ717641A (en) 2017-09-29
HRP20191416T1 (hr) 2019-11-15
EP2365829A4 (en) 2011-10-19
IL245427A0 (en) 2016-06-30
US20200330783A1 (en) 2020-10-22
NZ592650A (en) 2013-05-31
EA026962B1 (ru) 2017-06-30
KR101810148B1 (ko) 2017-12-19
NZ610404A (en) 2014-11-28
BRPI0920926B1 (pt) 2017-04-04
KR20170031259A (ko) 2017-03-20
CN102256591A (zh) 2011-11-23
AU2009311239B2 (en) 2012-11-15
CA2935819A1 (en) 2010-05-14
PL2365829T3 (pl) 2018-01-31
CA2742942A1 (en) 2010-05-14
HK1211478A1 (zh) 2016-05-27
US20110218482A1 (en) 2011-09-08
JP2016193951A (ja) 2016-11-17
US9597349B2 (en) 2017-03-21
MX376877B (es) 2025-03-07
JP2012508189A (ja) 2012-04-05
DK2365829T3 (en) 2017-07-31
KR20180023070A (ko) 2018-03-06
CA2742943A1 (en) 2010-05-14
CA2936527C (en) 2022-05-17
SI2352488T1 (sl) 2017-07-31
CY1118716T1 (el) 2017-07-12
JP2017160271A (ja) 2017-09-14
US20140221901A1 (en) 2014-08-07
ES2632717T3 (es) 2017-09-15
LT2365829T (lt) 2017-10-25
EA029534B1 (ru) 2018-04-30
IL212559A0 (en) 2011-06-30
US8632822B2 (en) 2014-01-21
CA2742943C (en) 2016-09-13
US10758744B2 (en) 2020-09-01
US20190366113A1 (en) 2019-12-05
US20190143137A1 (en) 2019-05-16
WO2010051636A1 (en) 2010-05-14
US20140221903A1 (en) 2014-08-07
JP2012508190A (ja) 2012-04-05
US20110224599A1 (en) 2011-09-15
EP2352488A4 (en) 2012-04-25
AU2009311234B2 (en) 2013-05-02
JP2016193950A (ja) 2016-11-17
BRPI0920926A2 (pt) 2016-09-20
MX2011004865A (es) 2011-10-17
US10485986B2 (en) 2019-11-26
JP2013253109A (ja) 2013-12-19
EP2352488B1 (en) 2017-01-04
US20170143989A1 (en) 2017-05-25
JP6453388B2 (ja) 2019-01-16
JP5827654B2 (ja) 2015-12-02
US8911791B2 (en) 2014-12-16
US20150065453A1 (en) 2015-03-05
KR101717792B1 (ko) 2017-03-17
WO2010051641A1 (en) 2010-05-14
AU2009311239A1 (en) 2010-05-14
IL251534A0 (en) 2017-05-29
CA2936527A1 (en) 2010-05-14
MX337084B (es) 2016-02-10
CN102256591B (zh) 2016-02-10
NZ631218A (en) 2016-03-31
US11020609B2 (en) 2021-06-01
JP6166825B2 (ja) 2017-07-19
IL212560A0 (en) 2011-06-30
JP5478632B2 (ja) 2014-04-23
PT2352488T (pt) 2017-03-20
JP2017160277A (ja) 2017-09-14
US9375446B2 (en) 2016-06-28
ES2618802T3 (es) 2017-06-22
JP5815622B2 (ja) 2015-11-17
EP2365829B1 (en) 2017-05-24
DK2352488T3 (en) 2017-03-27
US20130165845A1 (en) 2013-06-27
CN102300587A (zh) 2011-12-28
EP3150210A1 (en) 2017-04-05
PT2365829T (pt) 2017-07-17
CN105640987B (zh) 2020-04-14
HRP20171022T1 (hr) 2017-09-22
EA201170651A1 (ru) 2011-12-30
US8658219B2 (en) 2014-02-25
EA024827B1 (ru) 2016-10-31
EA201690702A1 (ru) 2016-11-30
KR20110094017A (ko) 2011-08-19
US8986745B2 (en) 2015-03-24
KR20170141807A (ko) 2017-12-26
CN105640987A (zh) 2016-06-08
SMT201700155T1 (it) 2017-05-08
EA024725B1 (ru) 2016-10-31
AU2009311234A1 (en) 2010-05-14
HRP20170343T1 (hr) 2017-06-16
US8637086B2 (en) 2014-01-28
LT2352488T (lt) 2017-05-25
IL212559A (en) 2016-06-30
EA201170650A1 (ru) 2011-12-30
JP6167213B2 (ja) 2017-07-19
HUE032192T2 (en) 2017-09-28
BRPI0921269A2 (pt) 2018-10-16
NZ592651A (en) 2013-05-31
JP2016006120A (ja) 2016-01-14
DK3150210T3 (da) 2019-09-02
US20210283417A1 (en) 2021-09-16
EP3205355A1 (en) 2017-08-16
US11691025B2 (en) 2023-07-04
ES2743314T3 (es) 2020-02-18
IL212560A (en) 2017-04-30
EP2365829A1 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
CN102300587B (zh) 用于伤口愈合的氧化剂和光活化剂的组合物
AU2013211509B2 (en) Combination of an oxidant and a photoactivator for the healing of wounds
HK1162307B (zh) 用於伤口癒合的氧化剂和光活化剂的组合物
HK1162307A (zh) 用於伤口癒合的氧化剂和光活化剂的组合物
AU2016234889A1 (en) Combination of an oxidant and a photoactivator for the healing of wounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20201102

Address after: Room 603, 6 / F, building 8, No. 6, Nanjiang 2nd Road, Zhujiang street, Nansha District, Guangzhou City, Guangdong Province (office only)

Patentee after: Guangdong koloc biomedical Group Co.,Ltd.

Address before: Quebec

Patentee before: KLOX TECHNOLOGIES Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231121

Address after: Room 16-1602, Building 8 (Building 9), No. 6, Nanjiang Second Road, the Pearl River Street, Nansha District, Guangzhou, Guangdong 510000

Patentee after: Kehuan Skin Management Technology (Guangdong) Co.,Ltd.

Address before: 511458 room 603, 6 / F, building 8, No. 6, Nanjiang 2nd Road, Zhujiang street, Nansha District, Guangzhou City, Guangdong Province (office only)

Patentee before: Guangdong koloc biomedical Group Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150401